MXPA05004845A - N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia. - Google Patents

N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.

Info

Publication number
MXPA05004845A
MXPA05004845A MXPA05004845A MXPA05004845A MXPA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A MX PA05004845 A MXPA05004845 A MX PA05004845A
Authority
MX
Mexico
Prior art keywords
derivatives
oxides
melphalan
states associated
inducible factor
Prior art date
Application number
MXPA05004845A
Other languages
English (en)
Spanish (es)
Inventor
J Welsh Sarah
Original Assignee
Prolx Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolx Pharmaceuticals Corp filed Critical Prolx Pharmaceuticals Corp
Publication of MXPA05004845A publication Critical patent/MXPA05004845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05004845A 2002-11-06 2003-11-03 N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia. MXPA05004845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/288,888 US20040087556A1 (en) 2002-11-06 2002-11-06 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
PCT/US2003/035226 WO2004043359A2 (en) 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor

Publications (1)

Publication Number Publication Date
MXPA05004845A true MXPA05004845A (es) 2005-10-05

Family

ID=32175991

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004845A MXPA05004845A (es) 2002-11-06 2003-11-03 N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.

Country Status (7)

Country Link
US (2) US20040087556A1 (enExample)
EP (1) EP1567476A4 (enExample)
JP (1) JP2006508124A (enExample)
AU (1) AU2003291282B2 (enExample)
CA (1) CA2504496C (enExample)
MX (1) MXPA05004845A (enExample)
WO (1) WO2004043359A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049309A1 (en) * 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
US20110092595A1 (en) * 2008-02-15 2011-04-21 Garth Powis Compositions and Methods for Treating Lung Cancer
WO2012058325A1 (en) * 2010-10-29 2012-05-03 Oncothyreon Inc. Compounds and methods useful for treatment of diseases mediated by hif-1
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
EP3102194A1 (en) 2014-02-03 2016-12-14 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
US10349839B2 (en) * 2015-02-27 2019-07-16 Biotronik Se & Co. Implantable pressure sensor device
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
US10842812B2 (en) 2015-08-12 2020-11-24 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2020146758A1 (en) 2019-01-10 2020-07-16 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602278A (en) * 1994-10-20 1997-02-11 Kirkpatrick; Lynn N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells

Also Published As

Publication number Publication date
WO2004043359B1 (en) 2004-10-28
US7399785B2 (en) 2008-07-15
CA2504496A1 (en) 2004-05-27
AU2003291282A1 (en) 2004-06-03
EP1567476A2 (en) 2005-08-31
EP1567476A4 (en) 2008-09-24
JP2006508124A (ja) 2006-03-09
CA2504496C (en) 2010-05-04
US20050026872A1 (en) 2005-02-03
WO2004043359A3 (en) 2004-09-10
AU2003291282B2 (en) 2010-11-11
WO2004043359A2 (en) 2004-05-27
US20040087556A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
EA200600317A1 (ru) Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE165825T1 (de) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
WO2004043359A3 (en) N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
MX2022006281A (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
ES2073258T3 (es) Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica.
MX2022006370A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso.
ATE286050T1 (de) Heterozyclische oder benzol derivate von liponsäure, deren herstellung und deren verwendung als heilmittel
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DE502005008351D1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
BR0313000A (pt) Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE275558T1 (de) 4-arylpiperidinderivate zur behandlung von pruritus
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
FG Grant or registration